

Topoisomerase II β -Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxicity and Prevention by Dexrazoxane

Yi Lisa Lyu, John E. Kerrigan, Chao-Po Lin, Anna M. Azarova, Yuan-Chin Tsai, Yi Ban, and Leroy F. Liu

Department of Pharmacology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey

Abstract

Doxorubicin is among the most effective and widely used anticancer drugs in the clinic. However, cardiotoxicity is one of the life-threatening side effects of doxorubicin-based therapy. Dexrazoxane (Zinecard, also known as ICRF-187) has been used in the clinic as a cardioprotectant against doxorubicin cardiotoxicity. The molecular basis for doxorubicin cardiotoxicity and the cardioprotective effect of dexrazoxane, however, is not fully understood. In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal γ -H2AX induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes. Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in *top2 β* ^{-/-} mouse embryonic fibroblasts (MEF) compared with *TOP2 β* ^{+/+} MEFs, suggesting the involvement of proteasome and DNA topoisomerase II β (Top2 β). Furthermore, in addition to antagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of Top2 β , which paralleled the reduction of doxorubicin-induced DNA damage. Together, our results suggest that dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2 β , which could implicate Top2 β in doxorubicin cardiotoxicity. The specific involvement of proteasome and Top2 β in doxorubicin-induced DNA damage is consistent with a model in which proteasomal processing of doxorubicin-induced Top2 β -DNA covalent complexes exposes the Top2 β -concealed DNA double-strand breaks. [Cancer Res 2007;67(18):8839-46]

Introduction

Doxorubicin (Adriamycin), a topoisomerase II (Top2)-targeting drug, is one of the most effective anticancer drugs used in the clinic. However, doxorubicin-based chemotherapy could result in, among other toxic side effects, life-threatening cardiotoxicity. Patients receiving a cumulative doxorubicin dose of ≥ 500 mg/m² have significantly increased risk of developing cardiac toxicity, including cardiomyopathy and congestive heart failure (1-4). Despite the severity of this dose-limiting toxicity, the molecular mechanism underlying doxorubicin cardiotoxicity remains unclear.

Requests for reprints: Yi Lisa Lyu and Leroy F. Liu, Department of Pharmacology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854-5635. Phone: 732-235-4592; E-mail: lyuyi@umdnj.edu and lliu@umdnj.edu.

©2007 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-07-1649

Currently, the free radical hypothesis is most favored due to the redox cycling ability of doxorubicin (an anthraquinone; refs. 1-4) to generate highly reactive oxygen free radicals.

The cardioprotectant dexrazoxane (Zinecard, also known as ICRF-187) is currently in clinical use to protect against doxorubicin cardiotoxicity (5). The mechanism for the protection has been primarily attributed to iron chelation by the EDTA-like hydrolysis product of dexrazoxane (4), which could decrease the level of hydroxyl free radicals through its chelation of iron (6, 7). However, cardioprotection through iron chelation is still controversial, as the iron chelator ICL670A (deferasirox) shows no protection against doxorubicin despite its efficient iron chelating capability and rapid intracellular distribution (8). Several other free radical scavengers also fail to rescue doxorubicin cardiotoxicity (1).

Dexrazoxane belongs to a class of molecules, bis(2,6-dioxopiperazines), which are known to function as Top2 catalytic inhibitors (9). These compounds are known to antagonize the formation of Top2-DNA covalent (cleavage) complexes through its stabilization of the ATP-bound closed-clamp conformation of Top2 that is unable to access chromosomal DNA (10). In addition, a bis(2,6-dioxopiperazines) derivative, ICRF-193, has been shown to induce degradation of Top2 β through a proteasome-dependent pathway (11). It is currently unclear whether the cardioprotective effect of dexrazoxane may involve Top2.

It is well established that the antitumor activity of doxorubicin is due to the formation of a Top2-doxorubicin-DNA ternary complex (the cleavable or cleavage complex; refs. 12-14). There are two Top2 isozymes, Top2 α and Top2 β , in mammalian cells (15). Doxorubicin, as well as other Top2-directed anticancer drugs such as etoposide (VP-16), amsacrine, and mitoxantrone, targets both isozymes (16, 17). However, the two Top2 isozymes are regulated very differently (18-21). Top2 α , which is only expressed in proliferating and tumor cells, plays important roles in cell cycle events, such as DNA replication, chromosome condensation/decondensation, and sister chromatid segregation (15). The high efficacy of doxorubicin chemotherapy is thought to be due to the highly elevated expression of Top2 α in cancer cells. By contrast, Top2 β is present in all cells, including postmitotic cells (18, 20, 22, 23). Recent studies have suggested that Top2 β may play a role in transcription (24, 25). Furthermore, VP-16 has been shown to induce preferential degradation of the Top2 β isozyme through a proteasome pathway, which presumably is responsible for the exposure of Top2 β -concealed DNA double-strand breaks (DSB; ref. 26). Indeed, recent studies have suggested that the Top2 β isozyme is predominantly responsible for the carcinogenic side effect associated with VP-16 chemotherapy (27). However, the role of Top2 β in doxorubicin cardiotoxicity is not known. It is noteworthy, however, that Top2 β , but not Top2 α , is expressed in adult heart (18).

In the present study, we show that dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2 β , which could implicate Top2 β in doxorubicin cardiotoxicity.

Materials and Methods

Cell culture and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. TOP2 $\beta^{+/+}$ and top2 $\beta^{-/-}$ primary mouse embryonic fibroblasts (MEF) were isolated from E13.5 mouse embryos following standard protocols (28). MEFs and H9C2 cardiomyocytes were maintained in DMEM supplemented with 10% FetalPlex animal serum complex (Gemini Bio-Products), L-glutamine (2 mmol/L), penicillin (100 units/mL), and streptomycin (100 μ g/mL) in a CO₂ (5%) incubator at 37°C. To assay doxorubicin cytotoxicity in MEFs, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was done. MEFs (1.1×10^4) were seeded in 96-well plates for 48 h. Cells were treated with 0.1% DMSO (solvent control) or 200 μ mol/L dexrazoxane for 5 h followed by coinubation with doxorubicin for 1 day or VP-16 for 2 days. MTT (0.1 mg) was then added to each well and cells were incubated for an additional 4 h at 37°C. After removal of medium, DMSO was added and absorbance at 570 nm was measured using the Microplate Reader (Bio-Rad). Average IC₅₀ values (mean \pm SE) were determined in triplicate or quadruplicate.

Immunoblotting. Cells were lysed in 3 \times SDS sample buffer [175 mmol/L Tris-HCl (pH 6.8), 15% glycerol, 5% SDS, 300 mmol/L DTT, 0.006% bromophenol blue] followed by boiling for 10 min. Cell lysates were then analyzed by SDS-PAGE. Western blotting was done using anti- γ -H2AX (JBW301, Upstate) and anti- α -tubulin (Developmental Studies Hybridoma Bank) antibodies followed by detection using enhanced chemiluminescence reagents (Pierce). Chemiluminescence signals were then captured using X-ray films or the Kodak Image Station 2000R (for quantification).

Neutral comet assay. Primary MEFs were treated with DMSO or doxorubicin for 1.5 h in a CO₂ incubator at 37°C followed by additional 30-min incubation in fresh medium to reverse Top2 cleavage complexes. H9C2 cells were treated with DMSO or dexrazoxane (100 μ mol/L) for 3 h, washed, and replenished with fresh medium. Cells were then treated with DMSO or doxorubicin for 1.5 h followed by additional 30-min incubation in fresh medium to reverse Top2 cleavage complexes. Cells were then washed and trypsinized using 0.005% trypsin and resuspended in DMEM supplemented with 10% FetalPlex animal serum complex (10,000/mL). Cell suspension (50 μ L) was then mixed with 500 μ L 0.5% low-melting point agarose at 37°C. Cell/agarose mixture (75 μ L) was transferred onto glass slides. Slides were then immersed in prechilled lysis buffer [2.5 mol/L NaCl, 100 mmol/L EDTA, 10 mmol/L Tris (pH 10.0), 1% Triton X-100, 10% DMSO] for 1 h followed by equilibration in 1 \times Tris-borate EDTA (TBE) buffer for 30 min. Slides were electrophoresed in 1 \times TBE at 1.0 V/cm for 10 min and stained with Vistra Green (Amersham Biosciences). Images were visualized under a fluorescence microscope and captured with a charge-coupled device camera. The average comet tail moment was determined from measuring at least 100 cells for each treatment group as described previously (26). Statistical analysis of the mean comet tail moments was done using Student's *t* test.

Band depletion assay. H9C2 cells (1.2×10^5) were treated with 250 μ mol/L VP-16 in the presence or absence of dexrazoxane (150 μ mol/L) for 15 min. Cells were either lysed immediately or incubated in drug-free medium for another 30 min at 37°C (to reverse Top2 cleavage complexes) before lysis. Cell lysates were analyzed by Western blotting using the anti-Top2 α /Top2 β (obtained from Dr. Jaulang Hwang, Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan) and anti- α -tubulin antibody. The amount of Top2 cleavage complexes can be estimated from the difference between the amount of free Top2 after reversal and the amount of free Top2 without reversal.

Homology modeling of the NH₂-terminal ATPase domain of human Top2 α and Top2 β in complex with dexrazoxane. The Modeller (8v2) program was used for construction of the homology models based on the crystal structure of the yeast Top2 ATPase domain in complex with dexrazoxane (ICRF-187; refs. 29–31). The template structure (1QZR.PDB) used to build the model has missing residues and side chains (10). The

missing side chains and residues in this structure were replaced and refined using the profix program from the Jackal suite of programs (32–34). The positions of dexrazoxane, ADPNP, and magnesium ions were taken from the yeast crystal structure template (10). The variables for dexrazoxane and the cofactor, ADPNP, were derived from the Amber 9 Antechamber program (35). Partial atomic charges were computed using the AM1-BCC method (36). Each structure model was coarsely refined using the Amber ff03 (37) and general Amber force field with the following energy minimization protocol: 500 steps steepest descents followed by 1,500 steps of conjugate gradient (38, 39).

Results

Dexrazoxane abolishes doxorubicin-induced DNA damage in H9C2 cardiomyocytes. Doxorubicin is known to have two major activities, poisoning of Top2 and induction of reactive oxygen species (ROS) through redox cycling, both of which are known to cause DNA damage. In the current study, we tested whether dexrazoxane could prevent doxorubicin-induced DNA damage in H9C2 cardiomyocytes and determined the molecular mechanism for this effect. As shown in Fig. 1A, doxorubicin induced the DNA damage signal γ -H2AX (Ser¹³⁹-phosphorylated H2AX, a key DNA damage signal induced by DNA DSBs) in H9C2 cardiomyocytes. Doxorubicin-induced γ -H2AX was concentration dependent up to 1 μ mol/L. At higher concentrations of doxorubicin




Figure 1. Dexrazoxane reduces doxorubicin-induced DNA damage. **A**, 1.5×10^5 H9C2 cardiomyocytes were treated with 0, 0.1, 0.5, 1, 5, and 10 μ mol/L of doxorubicin (Doxo) in the presence (+dexrazoxane) or absence (-dexrazoxane) of dexrazoxane (200 μ mol/L) for 1 h. Cell lysates were analyzed by Western blotting using anti- γ -H2AX or anti- α -tubulin antibody (for assessing protein loading). **B**, H9C2 cardiomyocytes were treated with 0.1% DMSO (C; for solvent control), 0.1 or 1 μ mol/L doxorubicin, 5 μ mol/L VP-16 (VP), 10 μ mol/L camptothecin (CPT), or 100 μ mol/L H₂O₂ in the presence or absence of dexrazoxane (200 μ mol/L) for 1 h. Cells were then lysed and analyzed by Western blotting using anti- γ -H2AX or anti- α -tubulin antibody. **C**, H9C2 cardiomyocytes were treated with 0.1% DMSO (for solvent control), 0.5 μ mol/L doxorubicin, or 10 μ mol/L VP-16 in the presence (+ICRF-193) or absence (-ICRF-193) of ICRF-193 (50 μ mol/L) for 1 h. Cells were then lysed and analyzed by Western blotting using anti- γ -H2AX or anti- α -tubulin antibody.




Figure 2. Doxorubicin-induced DNA damage is proteasome dependent. *A*, H9C2 cardiomyocytes were treated with 0.1% DMSO (for solvent control), 0.5 μ mol/L doxorubicin, or 10 μ mol/L VP-16 for 1 h in the presence or absence of 100 μ g/mL vitamin C (*top*) or 100 μ g/mL *N*-acetylcysteine (NAC; *bottom*). Vitamin C and *N*-acetylcysteine were added 30 min before doxorubicin. Cell lysates were then analyzed by Western blotting using anti- γ -H2AX or anti- α -tubulin antibody. *B*, H9C2 cardiomyocytes were treated with 0.1% DMSO (solvent control), 0.5 μ mol/L doxorubicin, or 10 μ mol/L VP-16 for 1 h in the presence or absence of either 1 μ mol/L bortezomib or 4 μ mol/L MG132. Bortezomib and MG132 were added 30 min before doxorubicin or VP-16. Cell lysates were then analyzed by Western blotting (*top*) using anti- γ -H2AX or anti- α -tubulin antibody. *Bottom*, quantification of γ -H2AX signals. *C*, H9C2 cells were treated with 0.1% DMSO, 1 μ mol/L bortezomib, or 4 μ mol/L MG132 for 30 min followed by cotreatment with either 0.1% DMSO (*control*) or 0.5 μ mol/L doxorubicin for 1.5 h. Neutral comet assay was then done as described in Materials and Methods. The average comet tail moments were plotted as histograms. *Columns*, mean; *bars*, SE. *, $P < 0.001$, *t* test.

(5 and 10 μ mol/L), the γ -H2AX signal was dramatically reduced. This pattern of concentration-dependent inhibition is reminiscent of dose-dependent inhibition of doxorubicin-induced Top2 cleavable/cleavage complexes (12). In the presence of dexrazoxane (200 μ mol/L), the doxorubicin-induced γ -H2AX signal was completely blocked. This blocking effect seemed to be specific to Top2-directed drugs, such as doxorubicin and VP-16 (Fig. 1*B*). γ -H2AX induced by camptothecin (a topoisomerase I poison) and H_2O_2 in H9C2 cardiomyocytes could not be blocked by cotreatment with dexrazoxane (Fig. 1*B*).

To test whether the blocking effect of dexrazoxane was due to inhibition of Top2, another well-characterized Top2 catalytic inhibitor, ICRF-193, was also tested. As shown in Fig. 1*C*, both the doxorubicin-induced (0.5 μ mol/L) and the VP-16-induced (10 μ mol/L) DNA damage signal, γ -H2AX, was indeed abolished by cotreatment with ICRF-193 (Fig. 1*C*).

Doxorubicin-induced DNA damage is blocked by proteasome inhibitors. Doxorubicin-induced DNA damage could be due to either Top2-DNA covalent (cleavable/cleavage) complexes or ROS. As shown in Fig. 2*A*, doxorubicin-induced γ -H2AX was unaffected by the known ROS scavengers, vitamin C (100 μ g/mL) and *N*-acetylcysteine (100 μ g/mL). By contrast, as shown in Fig. 2*B*, the proteasome inhibitors bortezomib (1 μ mol/L) and MG132 (4 μ mol/L) significantly reduced (>50% reduction, see Fig. 2*B*, *bottom* for quantification) the γ -H2AX signal induced by doxorubicin and VP-16. Recent studies have suggested that proteasomal processing of VP-16-induced Top2-DNA covalent complexes results in the exposure of Top2-concealed DSBs (26). Thus, the involvement of proteasome in doxorubicin-induced γ -H2AX could implicate the involvement of Top2 in doxorubicin-induced DNA damage.

To test whether DSBs were indeed induced by doxorubicin and prevented by proteasome inhibitors, a neutral comet assay was done. As shown in Fig. 2*C*, doxorubicin-induced comet tail moment, which reflects the amount of chromosomal DNA DSBs, was significantly reduced by cotreatment with either bortezomib ($P < 0.001$, *t* test) or MG132 ($P < 0.001$, *t* test). These results further

suggest that, similar to VP-16-induced DSBs, doxorubicin-induced DSBs are also Top2 mediated and proteasome dependent.

Doxorubicin-induced DNA damage is Top2 β mediated. The Top2 β , but not the Top2 α , isozyme is expressed in adult heart (18). To test whether Top2 β is involved in doxorubicin-induced DNA damage, doxorubicin-induced γ -H2AX was measured in primary MEFs isolated from *TOP2 β ^{+/+}* (wild-type) and *top2 β ^{-/-}* (*top2 β* knockout) embryos. As shown in Fig. 3*A*, doxorubicin-induced γ -H2AX was greatly reduced in *top2 β ^{-/-}* MEFs compared with *TOP2 β ^{+/+}* MEFs. Similarly, γ -H2AX induced by VP-16 was also greatly reduced in *top2 β ^{-/-}* MEFs (Fig. 3*B*). By contrast, γ -H2AX was induced by H_2O_2 and camptothecin to a similar extent in *top2 β ^{-/-}* and *TOP2 β ^{+/+}* MEFs (Fig. 3*B*). These results suggest that the doxorubicin-induced DNA damage signal γ -H2AX is primarily Top2 β mediated in MEFs.

We have also investigated the role of Top2 β in doxorubicin-induced chromosomal DNA DSBs using the neutral comet assay. Primary *TOP2 β ^{+/+}* and *top2 β ^{-/-}* MEFs were treated with doxorubicin for 1.5 h followed by incubation in drug-free medium for 30 min to reverse doxorubicin-trapped Top2 cleavage complexes. Neutral comet assay was then done to analyze the formation of DSBs. As shown in Fig. 3*C*, doxorubicin (0.5 and 1 μ mol/L) treatment led to a 2-fold increase in comet tail moment compared with control treatment (0.1% DMSO) in *TOP2 β ^{+/+}* MEFs ($P < 0.001$, *t* test; *white columns*), whereas no significant increase ($P > 0.2$, *t* test) in comet tail moment was observed in doxorubicin-treated *top2 β ^{-/-}* MEFs (*black columns*). These results suggest that doxorubicin-induced DSBs are primarily Top2 β mediated in MEFs.

In addition to doxorubicin-induced DNA damage, we also investigated the role of Top2 β and the effect of dexrazoxane on doxorubicin cytotoxicity using MTT assay in confluent (to reduce the contribution from Top2 α) primary MEFs. *top2 β ^{-/-}* MEFs were shown to be more resistant to doxorubicin than *TOP2 β ^{+/+}* MEFs. The IC_{50} of doxorubicin in *top2 β ^{-/-}* MEFs (2.85 ± 0.10 μ mol/L) was significantly higher compared with that in *TOP2 β ^{+/+}* MEFs (0.95 ± 0.06 μ mol/L; $P < 0.05$, *t* test), suggesting a major role of




Figure 3. Induction of Top2 β -mediated chromosomal DNA DSBs by doxorubicin in primary MEFs. *A*, 2×10^5 primary *top2\beta*^{-/-} and *TOP2\beta*^{+/+} MEFs were treated with 0, 0.1, 0.5, 1, 5, and 10 $\mu\text{mol/L}$ of doxorubicin for 1 h. Cells were lysed and analyzed by Western blotting using either anti- γ -H2AX or anti- α -tubulin antibody. *B*, primary *top2\beta*^{-/-} and *TOP2\beta*^{+/+} MEFs were either untreated (for control) or treated with H₂O₂ (30 or 150 $\mu\text{mol/L}$), camptothecin (1 or 10 $\mu\text{mol/L}$), or VP-16 (100 $\mu\text{mol/L}$) for 1 h. Cell lysates were analyzed by Western blotting as described in (A). *C*, primary *top2\beta*^{-/-} and *TOP2\beta*^{+/+} MEFs were treated with 0 (control; 0.1% DMSO was added as solvent control), 0.5, or 1 $\mu\text{mol/L}$ of doxorubicin for 1.5 h and neutral comet assay was then done as described in Materials and Methods. Average comet tail moments were plotted as histograms. Columns, mean; bars, SE.

Top2 β in doxorubicin cytotoxicity in primary MEFs. Consistent with this interpretation, *top2\beta*^{-/-} MEFs were also shown to be significantly more resistant to VP-16 (another Top2 poison; IC₅₀ = 47.3 \pm 4.3 $\mu\text{mol/L}$) compared with *TOP2\beta*^{+/+} MEFs (IC₅₀ = 28.3 \pm 1.0 $\mu\text{mol/L}$; $P < 0.05$, *t* test). As a control, the growth-inhibitory activity of H₂O₂ was also determined and shown to be the same in *top2\beta*^{-/-} MEFs and *TOP2\beta*^{+/+} MEFs (IC₅₀ = 0.2 mmol/L). In addition, dexrazoxane (200 $\mu\text{mol/L}$) also significantly increased (2- to 3-fold) the IC₅₀ of doxorubicin (2.18 \pm 0.16 $\mu\text{mol/L}$) and VP-16 (95.8 \pm 1.9 $\mu\text{mol/L}$) in *TOP2\beta*^{+/+} MEFs ($P < 0.05$, *t* test). By contrast, dexrazoxane had no effect on the growth-inhibitory activity of H₂O₂ in *TOP2\beta*^{+/+} MEFs (IC₅₀ = 0.2 mmol/L). These results suggest that doxorubicin cytotoxicity is Top2 β dependent and dexrazoxane can protect doxorubicin cytotoxicity in primary MEFs.

Dexrazoxane induces proteasomal degradation of Top2 β in cardiomyocytes. Our results suggest that Top2 β plays an important role in doxorubicin cytotoxicity and doxorubicin-induced DNA damage in primary MEFs. However, it is unclear how dexrazoxane antagonizes doxorubicin cytotoxicity and doxorubicin-induced DNA damage. One possibility is that dexrazoxane antagonizes the formation of doxorubicin-induced Top2 cleavage complexes because dexrazoxane has been shown to reduce Top2

drug-induced protein-DNA cross-links as well as DNA single-strand breaks as monitored by alkaline elution assay (40). Indeed, as shown in Fig. 4A, VP-16 trapped both Top2 α (~70% depleted in free Top2 α) and Top2 β (~70% depleted in free Top2 β) into Top2-DNA covalent complexes to a similar extent (compare lanes 2 and 3) as evidenced by a band depletion assay. On the other hand, the




Figure 4. Dexrazoxane induces proteasomal degradation of Top2 β in H9C2 cardiomyocytes. *A*, dexrazoxane antagonizes the formation of Top2 α and Top2 β -DNA covalent (cleavage) complexes. H9C2 cells were treated with VP-16 in the presence or absence of dexrazoxane (150 $\mu\text{mol/L}$) for 15 min. The amount of Top2 cleavage complexes was measured by a band depletion assay as described in Materials and Methods. Cells were lysed either immediately or after reversal of the Top2 cleavage complexes (*R*+250). Cell lysates were analyzed by Western blotting using anti-Top2 α /Top2 β or anti- α -tubulin antibody. *B*, 1.2×10^5 H9C2 cells were treated with 100 $\mu\text{mol/L}$ dexrazoxane for indicated times (0, 1, 2, 4, and 6 h). Cells were then lysed and protein levels of Top2 α and Top2 β isozymes were determined by Western blotting. *C*, H9C2 cells were treated with 0.1% DMSO (for solvent control), dexrazoxane (100 $\mu\text{mol/L}$), or ICRF-193 (50 $\mu\text{mol/L}$) for 2 or 4 h in the presence or absence of the proteasome inhibitor bortezomib (1 $\mu\text{mol/L}$). Cell lysates were immunoblotted using anti-Top2 β antibody. *D*, H9C2 cells were treated with ICRF187 (100 $\mu\text{mol/L}$) for 4 h followed by treatment with doxorubicin (0, 0.5, and 1 $\mu\text{mol/L}$) for 1.5 h. Neutral comet assay was then done as described in Materials and Methods. The average comet tail moments were plotted as histograms. Columns, mean; bars, SE. *, $P < 0.001$, *t* test.




Figure 5. Homology modeling of the NH₂-terminal ATPase domain of human Top2 α and Top2 β in complex with dexrazoxane. Homology modeled structures of the ATPase domain of human Top2 β (left) and Top2 α (right) in complex with dexrazoxane. Top, the Top2 isozyme dimers are symmetrical with the separate protein chains indicated in red and blue. ADPNP (green) and dexrazoxane (in Corey-Pauling-Koltun coloring) are shown using space-filling models. The dexrazoxane binding region (boxed in top left and top right) is composed of residues from both chains at the dimer interface. The bottom left and bottom right (both side view and top view) show the proximal residues in the dexrazoxane binding sites of human Top2 β (left) and Top2 α (right) in complex with dexrazoxane (yellow).

amount of VP-16-trapped Top2 α (~10% depleted) and Top2 β (~10% depleted) covalent complexes (compare lanes 5 and 6) was much reduced in the presence of dexrazoxane. These results suggest that dexrazoxane can effectively antagonize the formation of VP-16-induced Top2 α -DNA and Top2 β -DNA covalent (cleavage) complexes in H9C2 cardiomyocytes.

However, recent studies have also shown that a related compound, ICRF-193, can efficiently induce proteasome-mediated degradation of Top2 β (11). Degradation of Top2 β is also expected to reduce doxorubicin-induced DNA damage and doxorubicin cytotoxicity in H9C2 cells. We therefore tested the effect of dexrazoxane on the protein level of Top2 β in H9C2 cardiomyocytes. As shown in Fig. 4B, treatment of H9C2 cells with 100 μ mol/L dexrazoxane induced a time-dependent disappearance of the Top2 β isozyme, whereas no significant effect on the level of the Top2 α isozyme was observed. Similar to ICRF-193-induced degradation of Top2 β , dexrazoxane-induced degradation of Top2 β is proteasome mediated. As shown in Fig. 4C, cotreatment of H9C2 cardiomyocytes with the proteasome inhibitor bortezomib abolished dexrazoxane-induced degradation of Top2 β . These results suggest that dexrazoxane induces efficient proteasomal degradation of Top2 β in H9C2 cardiomyocytes.

To test whether dexrazoxane-induced Top2 β degradation could contribute to the protective effect of dexrazoxane on doxorubicin-induced DNA damage, H9C2 cardiomyocytes were pretreated with

dexrazoxane for 4 h to induce Top2 β degradation and doxorubicin-induced chromosomal DNA DSBs were then measured by the neutral comet assay in the absence of dexrazoxane. As shown in Fig. 4D, dexrazoxane pretreatment effectively reduced doxorubicin-induced comet tail moment ($P < 0.001$, t test). Together, these results suggest that dexrazoxane could protect doxorubicin-induced DNA damage at least in part through proteasomal degradation of Top2 β .

Dexrazoxane targets mammalian Top2 α and Top2 β isozymes. Our current studies have shown that dexrazoxane can antagonize the formation of both Top2 α and Top2 β cleavage complexes, suggesting the binding of dexrazoxane to both Top2 isozymes. On the other hand, our current studies have also shown that dexrazoxane induces specific degradation of the Top2 β , but not the Top2 α , isozyme, which could suggest specific binding of dexrazoxane to Top2 β isozyme. To clarify this issue, we did homology modeling studies of hTop2 α and hTop2 β in complex with dexrazoxane based on the structure of the cocrystal of dexrazoxane and the ATPase domain of yeast Top2 (see Materials and Methods; ref. 10).

As shown in Fig. 5, dexrazoxane was shown to form a tight complex with the ATPase domain of human Top2 β at the dimer interface. The overall structure of the human Top2 β -dexrazoxane complex is very similar to that of the yeast Top2-dexrazoxane complex (10). In addition, dexrazoxane forms various interactions




Figure 6. Two proposed mechanisms for the antagonistic effect of dexrazoxane on doxorubicin-induced DNA damage. In this model, only the role of the Top2 β isozyme is considered, which would mimic the situation in adult heart where Top2 β , but not Top2 α , is expressed. Top2 β is shown to exist in two states, free Top2 β (mechanism I) and DNA-bound Top2 β (mechanism II), at equilibrium. Dexrazoxane can bind to Top2 β in either state. For mechanism I, binding of dexrazoxane to free Top2 β stabilizes the closed-clamp conformation of ATP-bound Top2 β and thus prevents binding of Top2 β (closed clamp) to chromosomal DNA. Consequently, doxorubicin is unable to trap Top2 β into cleavage complexes. For mechanism II, dexrazoxane binds to DNA-bound Top2 β and stabilizes the closed-clamp conformation of ATP-bound Top2 β , which triggers proteasomal degradation of Top2 β (Top2 β down-regulation). Top2 β down-regulation results in depletion of Top2 β and thus fewer doxorubicin-trapped Top2 β cleavage complexes. The formation of doxorubicin-trapped Top2 β cleavage complexes leads to DNA DSBs through proteasome-mediated processing, which, if not repaired, could contribute to cell death and possible tissue toxicity (e.g., cardiotoxicity).

with the same conserved amino acid side chains (see amino acids at the binding sites in Fig. 5, *middle*) at the binding site of human Top2 β ATPase domain as those of the yeast Top2 ATPase domain. We have also done homology modeling of the human Top2 α (ATPase domain)-dexrazoxane complex. The overall structure of

the complex is very similar to that of the human Top2 β -dexrazoxane complex. Most strikingly, the various interactions between dexrazoxane and the amino acid side chains at the binding sites of the two human isozymes are identical (Fig. 5, *middle* and *bottom*). These modeling studies suggest that dexrazoxane can form a tight complex with both human Top2 isozymes.

Discussion

Doxorubicin is one of the most effective and widely used anticancer agents in the clinic. Being an anthraquinone and a strong DNA intercalator, doxorubicin has complex biological activities (41–43). The anticancer activity of doxorubicin has been attributed to its targeting of DNA Top2 by stabilizing a Top2-doxorubicin-DNA covalent complex, referred to as cleavable or cleavage complex (12). This anticancer activity is believed to be related to the ability of doxorubicin to intercalate DNA and hence poisoning of Top2. However, the life-threatening cardiotoxicity associated with the use of doxorubicin is believed to result from the redox cycling activity of doxorubicin due to its quinone moiety (1–4). Both the redox cycling activity, which generates ROS, and the Top2-targeting activity, which generates Top2-DNA covalent complexes, are expected to induce DNA damage. In the current study, we have determined the contribution of these two activities to doxorubicin-induced DNA damage.

We show that doxorubicin induces γ -H2AX, a key DNA damage signal reflecting primarily DNA DSBs, in H9C2 cardiomyocytes. Using this system, we have shown that the doxorubicin-induced DNA damage signal is unlikely to be the result of ROS-mediated DNA damage because vitamin C and *N*-acetylcysteine cannot attenuate this signal. Instead, several pieces of evidence suggest that the doxorubicin-induced DNA damage signal is primarily due to the formation of Top2-DNA covalent complexes. First, doxorubicin-induced γ -H2AX was shown to be specifically abolished by proteasome inhibitors MG132 and bortezomib. This result is suggestive of an involvement of Top2 because Top2-DNA covalent (cleavage) complexes, unlike other DNA damages (e.g., H₂O₂-mediated DNA damage), are known to require proteasome for their processing into DNA damage (DSBs; ref. 26). Indeed, doxorubicin is shown to induce chromosomal DNA DSBs in a proteasome-dependent manner (Fig. 2C and see the lower half of the diagram in Fig. 6 for the model). Second, doxorubicin-induced γ -H2AX is much attenuated in *top2 β ^{-/-}* MEFs compared with that in *TOP2 β ^{+/+}* MEFs, suggesting the involvement of Top2 β . Together, these results suggest the involvement of both Top2-DNA covalent complexes and proteasome in doxorubicin-induced DNA damage, which is consistent with the model that proteasome-mediated degradation of Top2-DNA covalent complexes exposes Top2-concealed DSBs (26).

We have also shown that dexrazoxane specifically abolished doxorubicin-induced and VP-16-induced, but not camptothecin- and H₂O₂-induced, γ -H2AX in H9C2 cardiomyocytes. Because both doxorubicin and VP-16, but not camptothecin and H₂O₂, are Top2 poisons, this result supports the conclusion that dexrazoxane antagonizes doxorubicin-induced DNA damage through its specific interference with Top2. Additional support for this conclusion comes from the use of ICRF-193 (structurally related to dexrazoxane, ICRF-187), which is a well-characterized Top2 catalytic activity inhibitor (9). ICRF-193, which is more potent than dexrazoxane in inhibiting Top2, is shown to be highly effective in antagonizing

doxorubicin-induced γ -H2AX in H9C2 cardiomyocytes. The fact that both dexrazoxane and ICRF-193 antagonize the doxorubicin-induced DNA damage signal suggests not only the involvement of Top2 but also a potential mechanism for their antagonism. Bis(2,6-dioxopiperazines), such as ICRF-193 and ICRF-159, are known to stabilize the closed-clamp conformation of ATP-bound Top2 (44, 45). It has been well documented that the closed-clamp conformation of Top2 interferes with the formation of Top2 cleavage complexes induced by Top2-directed drugs possibly due to the inability of the closed-clamp form of Top2 to access chromosomal DNA (46, 47). Consequently, dexrazoxane may antagonize doxorubicin-induced DNA damage through preventing the formation of Top2 cleavage complexes on chromosomal DNA [due to dexrazoxane stabilization of the closed-clamp conformation of Top2 (10), which is unable to access chromosomal DNA].

The identification of Top2 β as the major target of doxorubicin to induce DNA damage has suggested a possible new mechanism for the antagonistic effect of dexrazoxane on doxorubicin-induced DNA damage. ICRF-193 is known to induce preferential degradation of the Top2 β isozyme through a proteasome pathway, referred to as Top2 β down-regulation (11). The reduced Top2 β level in ICRF-193-treated cells is expected to decrease the amount of doxorubicin-induced Top2 β cleavage complexes and hence reduce DNA damage. Indeed, we have shown that dexrazoxane, like ICRF-193, is highly effective in reducing the level of Top2 β (but not Top2 α) in H9C2 cardiomyocytes through the activation of a proteasome pathway (Fig. 4). Consequently, dexrazoxane is likely to antagonize doxorubicin-induced DNA damage through two mechanisms: (a) direct interference with the formation of Top2 cleavage complexes and (b) Top2 β down-regulation.

At present, it is not clear whether the antagonistic effect of dexrazoxane on doxorubicin-induced DNA damage in H9C2 cardiomyocytes observed in the current study is relevant to the protective effect of dexrazoxane against doxorubicin cardiotoxicity in patients. However, it has been shown that the heart is one of the tissues that prominently express the *TOP2 β* mRNA in adult mice (18). Interestingly, the *TOP2 α* mRNA is completely absent in the heart but still detectable in some other adult tissues, such as the spleen and intestine (18). These findings indicate that Top2 β is the only Top2 isozyme that is present in the adult heart and suggest that Top2 β targeting by doxorubicin could contribute to its toxic side effects (i.e., cardiotoxicity). In addition, it is known that Top2 β can be detected in mitochondria (48) and doxorubicin can accumulate in mitochondria that are abundant in the heart (49). These results suggest that Top2 β targeting by doxorubicin in both nuclei and mitochondria of cardiomyocytes could contribute to doxorubicin cardiotoxicity. However, we cannot rule out the involvement of Top2 β -independent mechanism(s) (50) for doxorubicin cardiotoxicity, especially at higher doses of doxorubicin,

because the DNA damage signal γ -H2AX is significantly reduced at higher concentrations of doxorubicin (Figs. 1A and 3A).

Our current studies, therefore, may have relevance to doxorubicin cardiotoxicity. The two proposed mechanisms (see Fig. 6) for the antagonistic effect of dexrazoxane on doxorubicin-induced DNA damage may have interesting clinical implications. In mechanism I, dexrazoxane stabilizes the closed-clamp form of Top2 and thus prevents access of Top2 to chromosomal DNA. Consequently, doxorubicin is unable to trap Top2 on chromosomal DNA to form Top2-DNA covalent (cleavage) complexes. This mechanism is not Top2 isozyme specific because dexrazoxane can stabilize the closed-clamp forms of both Top2 α and Top2 β . In fact, our homology modeling studies of the human Top2 α and Top2 β in complex with dexrazoxane have indicated that the dexrazoxane binding sites are the same for the two isozymes, with identical interactions between dexrazoxane and the various amino acid side chains. There are increasing evidence that the antitumor activity of Top2-targeting drugs is primarily due to Top2 α targeting in part due to the overexpression of Top2 α in tumor cells. Consequently, dexrazoxane is expected to reduce the antitumor activity of doxorubicin through mechanism I.

By contrast, dexrazoxane can down-regulate the Top2 β isozyme specifically through mechanism II (Fig. 6). Through this mechanism, dexrazoxane is expected not to have a major effect on the Top2 α isozyme level and hence the antitumor activity of doxorubicin (and other Top2-targeting drugs). If indeed, dexrazoxane, used under the current clinical protocol, prevents doxorubicin cardiotoxicity through both mechanisms, strategies should be developed to prevent mechanism I and favor mechanism II. For example, proper timing of dexrazoxane pretreatment during doxorubicin-based chemotherapy may change the contribution through these two mechanisms.

The idea that Top2 targeting is involved in doxorubicin cardiotoxicity has significant clinical implications. It provides the rationale for developing Top2 α -specific anticancer drugs to prevent tissue toxicities (i.e., cardiotoxicity) in patients receiving Top2-based chemotherapy. It is also noteworthy that the involvement of proteasome in Top2 β -mediated DNA damage could suggest a novel approach for preventing doxorubicin cardiotoxicity through the combined use of bortezomib (or other proteasome inhibitor) and doxorubicin.

Acknowledgments

Received 5/7/2007; revised 6/11/2007; accepted 7/5/2007.

Grant support: NIH grant RO1CA102463 (L.F. Liu), Department of Defense Concept Award BC053409 (Y.L. Lyu), and Idea Award BC060915 (Y.L. Lyu).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Jaulang Hwang for providing the anti-Top2 antibody.

References

- De Beer EL, Bottone AE, Voest EE. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. *Eur J Pharmacol* 2001;415:1–11.
- Wallace KB. Doxorubicin-induced cardiac mitochondrialopathy. *Pharmacol Toxicol* 2003;93:105–15.
- Zucchi R, Danesi R. Cardiac toxicity of antineoplastic anthracyclines. *Curr Med Chem Anti-Canc Agents* 2003; 3:151–71.
- Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. *Mol Pharmacol* 2005;68:261–71.
- Hellmann K. Overview and historical development of dexrazoxane. *Semin Oncol* 1998;25:48–54.
- Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. *FASEB J* 1990;4:3076–86.
- Weiss G, Loyevsky M, Gordeuk VR. Dexrazoxane (ICRF-187). *Gen Pharmacol* 1999;32:155–8.
- Hasinoff BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. *Free Radic Biol Med* 2003;35: 1469–79.
- Andoh T. Bis(2,6-dioxopiperazines), catalytic inhibitors of DNA topoisomerase II, as molecular probes, cardioprotectors and antitumor drugs. *Biochimie* 1998; 80:235–46.
- Classen S, Olland S, Berger JM. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. *Proc Natl Acad Sci U S A* 2003;100:10629–34.
- Xiao H, Mao Y, Desai SD, et al. The topoisomerase

- II β circular clamp arrests transcription and signals a 26S proteasome pathway. *Proc Natl Acad Sci U S A* 2003;100:3239–44.
12. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. *Science* 1984;226:466–8.
13. Hong JH, Okada K, Kusano T, et al. Reduced DNA topoisomerase II in VP-16 resistant mouse breast cancer cell line. *Biomed Pharmacother* 1990;44:41–5.
14. Kuriyama M, Tsutsui K, Ono Y, et al. Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase II α . *Neurol Med Chir (Tokyo)* 1997;37:655–61; discussion 61–2.
15. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. *Nat Rev Mol Cell Biol* 2002;3:430–40.
16. Cornarotti M, Tinelli S, Willmore E, et al. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases II α (p170) and II β (p180). *Mol Pharmacol* 1996;50:1463–71.
17. Willmore E, Frank AJ, Padgett K, Tilby MJ, Austin CA. Etoposide targets topoisomerase II α and II β in leukemic cells: isoform-specific cleavable complexes visualized and quantified *in situ* by a novel immunofluorescence technique. *Mol Pharmacol* 1998;54:78–85.
18. Capranico G, Tinelli S, Austin CA, Fisher ML, Zunino F. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. *Biochim Biophys Acta* 1992;1132:43–8.
19. Tsutsui K, Okada S, Watanabe M, et al. Molecular cloning of partial cDNAs for rat DNA topoisomerase II isoforms and their differential expression in brain development. *J Biol Chem* 1993;268:19076–83.
20. Watanabe M, Tsutsui K, Inoue Y. Differential expressions of the topoisomerase II α and II β mRNAs in developing rat brain. *Neurosci Res* 1994;19:51–7.
21. Turley H, Comley M, Houlbrook S, et al. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. *Br J Cancer* 1997;75:1340–6.
22. Lyu YL, Wang JC. Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase II β . *Proc Natl Acad Sci U S A* 2003;100:7123–8.
23. Tsutsui K, Hosoya O, Sano K, Tokunaga A. Immunohistochemical analyses of DNA topoisomerase II isoforms in developing rat cerebellum. *J Comp Neurol* 2001;431:228–39.
24. Tsutsui K, Sano K, Kikuchi A, Tokunaga A. Involvement of DNA topoisomerase II β in neuronal differentiation. *J Biol Chem* 2001;276:5769–78.
25. Lyu YL, Lin CP, Azarova AM, et al. Role of topoisomerase II β in the expression of developmentally regulated genes. *Mol Cell Biol* 2006;26:7929–41.
26. Zhang A, Lyu YL, Lin CP, et al. A protease pathway for the repair of topoisomerase II-DNA covalent complexes. *J Biol Chem* 2006;281:35997–6003.
27. Azarova AM, Lyu YL, Lin CP, et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. *Proc Natl Acad Sci U S A* 2007;104:11014–9.
28. Hogan B, Beddington R, Constantini F, Lacy E. *Manipulating the mouse embryo: a laboratory manual*. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1994.
29. Fiser A, Do RK, Sali A. Modeling of loops in protein structures. *Protein Sci* 2000;9:1753–73.
30. Marti-Renom MA, Stuart AC, Fiser A, et al. Comparative protein structure modeling of genes and genomes. *Annu Rev Biophys Biomol Struct* 2000;29:291–325.
31. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. *J Mol Biol* 1993;234:779–815.
32. Xiang J. *A protein structure modeling package*. New York (NY): Columbia University; 2002.
33. Xiang Z, Honig B. Extending the accuracy limits of prediction for side-chain conformations. *J Mol Biol* 2001;311:421–30.
34. Xiang Z, Soto CS, Honig B. Evaluating conformational free energies: the colony energy and its application to the problem of loop prediction. *Proc Natl Acad Sci U S A* 2002;99:7432–7.
35. Wang J, Wang W, Kollman PA, Case DA. Antechamber, an accessory software package for molecular mechanics calculations. *J Mol Graphics* 2006;25:247–60.
36. Jakalian A, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. *J Comput Chem* 2002;23:1623–41.
37. Duan Y, Wu C, Chowdhury S, et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. *J Comput Chem* 2003;24:1999–2012.
38. Case DA, Cheatham TE III, Darden T, et al. The Amber biomolecular simulation programs. *J Comput Chem* 2005;26:1668–88.
39. Ponder JW, Case DA. Force fields for protein simulations. *Adv Protein Chem* 2003;66:27–85.
40. Sehested M, Jensen PB, Sorensen BS, et al. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). *Biochem Pharmacol* 1993;46:389–93.
41. Zunino F, Capranico G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. *Anticancer Drug Des* 1990;5:307–17.
42. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. *Drugs* 1997;54 Suppl 4:1–7.
43. Muller I, Niethammer D, Bruchelt G. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (review). *Int J Mol Med* 1998;1:491–4.
44. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. *Proc Natl Acad Sci U S A* 1994;91:1781–5.
45. Chang S, Hu T, Hsieh TS. Analysis of a core domain in *Drosophila* DNA topoisomerase II. Targeting of an antitumor agent ICRF-159. *J Biol Chem* 1998;273:19822–8.
46. Roca J, Wang JC. The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. *Cell* 1992;71:833–40.
47. Wang H, Mao Y, Zhou N, et al. ATP-bound topoisomerase II as a target for antitumor drugs. *J Biol Chem* 2001;276:15990–5.
48. Low RL, Orton S, Friedman DB. A truncated form of DNA topoisomerase II β associates with the mtDNA genome in mammalian mitochondria. *Eur J Biochem* 2003;270:4173–86.
49. Nicolay K, Fok JJ, Voorhout W, Post JA, de Kruijff B. Cytofluorescence detection of adriamycin-mitochondria interactions in isolated, perfused rat heart. *Biochim Biophys Acta* 1986;887:35–41.
50. Kurz EU, Douglas P, Lees-Miller SP. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. *J Biol Chem* 2004;279:53272–81.